Elevated levels of soluble glycoprotein V - The plasma marker of platelet activation by thrombin in patients with early stage primary biliary cholangitis (PBC)

Pawel Rogalski; Dagmara Bogdanowska-Charkiewicz; Magdalena Rogalska-Plonska; Marta Lukaszewicz-Zajac; Ines Kostecka-Roslen; Barbara Mroczko; Milena Dabrowska; Justyna Wasielica-Berger; Elzbieta Aleksiejuk; Stefania Antonowicz; Andrzej Dabrowski; Jaroslaw Daniluk; Jacek Janica

doi:10.1016/j.advms.2023.01.002

Elevated levels of soluble glycoprotein V - The plasma marker of platelet activation by thrombin in patients with early stage primary biliary cholangitis (PBC)

Adv Med Sci. 2023 Mar;68(1):71-78. doi: 10.1016/j.advms.2023.01.002. Epub 2023 Feb 7.

Affiliations

¹ Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland. Electronic address: pawel.rogalski@umb.edu.pl.
² Department of Gastroenterology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland.
³ Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
⁴ Department of Biochemical Diagnostics, Medical University of Bialystok, Bialystok, Poland.
⁵ Department of Haematological Diagnostics, Medical University of Bialystok, Bialystok, Poland.
⁶ Department of Radiology, Medical University of Bialystok, Bialystok, Poland; Department of Paediatric Radiology, Medical University of Bialystok, Bialystok, Poland.

PMID: 36758500
DOI: 10.1016/j.advms.2023.01.002

Abstract

Purpose: There is a growing body of evidence for a prothrombotic tendency in patients with primary biliary cholangitis (PBC). The aim of the study was to evaluate coagulation disorders in patients with early stage PBC compared to healthy controls and evaluation of their relationship with clinical data, with particular emphasis on minimal hepatic encephalopathy (MHE).

Patients and methods: Fifty-one participants (PBC group - 38 patients, all patients but one Child-Pugh A; control group - 13 healthy controls) were included in our prospective, single center study. We assessed the plasma levels of sGPV, plasma procoagulant phospholipids (PPL) and rotational thromboelastometry (ROTEM) profiles in all study participants. Porto-systemic encephalopathy syndrome test was used to assess MHE.

Results: The sGPV levels were higher in the PBC group compared to the controls: 36.07 ± 11.32 ng/mL vs 27.04 ± 11.72 ng/mL, p = 0.031. The PPL level was lower in the PBC group compared to controls resulting in increased clotting time in a factor Xa-based coagulation assay: 54.65 (47.83-58.83) sec. vs 45.90 (43.3-50.5) sec., p = 0.0065. PPL levels were correlated with platelet count (rho = -0.46, p = 0.001). ROTEM parameters did not differ significantly between groups. Coagulation parameters did not differ significantly between patients with and without MHE.

Conclusions: We have showed increased levels of sGPV - a plasma marker of platelet activation by thrombin in patients with early stage PBC compared to healthy controls. We found no relationship between the coagulation disorders and the occurrence of MHE. The PPL level was lower in the PBC group.

Keywords: Glycoprotein V; Plasma procoagulant phospholipids; Primary biliary cholangitis; Prothrombotic coagulation disorders; Thromboelastometry.

MeSH terms

Glycoproteins
Humans
Liver Cirrhosis, Biliary*
Platelet Activation
Prospective Studies
Thrombin*

Substances

Thrombin
Glycoproteins